Health information of nearly 20K children exposed in mailing error

The personal health information of nearly 20,000 children was exposed after a mailing error, according to a report by the Kansas City Star.

In the report, WellCare Health Plans said a mailing error caused reminders about well-child visits for its Missouri Care members to be sent to the wrong addresses, causing the health information of 19,570 children to be accidentally exposed. The company learned of the incident on July 25. 

“The letters contained personally identifiable health information including (the) child’s name, age and provider name,” Ted Webster, WellCare’s vice president and chief security and privacy officer, said in a letter cited in the report.

According to the report, Missouri Care plans cover about 275,000 people throughout the state of Missouri and mainly focus on children and pregnant women. The company said there’s no evidence that suggests the exposed information was misused, but it’s offering members one year of free credit monitoring from Experian.

“As we continue to investigate the scope of the incident, we are taking steps to prevent something like this from happening again,” Webster said in the letter. “Missouri Care is deeply committed to protecting our members’ privacy, and we apologize for any inconvenience this incident may have caused.”

To read the full story, click the link below. 

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.